Edward Li

The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug price

Biosimilar denosumab is a dominant treatment strategy (i.e., more effective and less costly) across varying levels of baseline fracture risk with sufficient price reductions. Given its superior efficacy and safety, it may be considered a first-line therapy for the treatment of wo...